Concord Biotech Ltd Company History

Incorporation of Servomed Pharmaceuticals Private Limited”

Change in the name to Concord Pharmaceuticals Private Limited”

Conversion to a deemed public company pursuant to Section 43A of Companies Act, 1956

Acquisition of the Company by Mr. Sudhir Vaid, one of the Promoters.

Renaming of the Company to Concord Biotech Limited”.

Expansion of production capacity of enzymes.

Certification of the facility at Dholka for commissioning and commencement of production of various enzymes by technical consultants.

Investment by Rakesh Jhunjhunwala and Rekha Jhunjhunwala in the Company.

First USFDA inspection and classification of the API facility as acceptable.

Second USFDA inspection and classification of the API facility as acceptable.

Received drug master file registration certificate for tacrolimus hydrate from Pharmaceuticals and Medical Devices Agency, Japan.

First EU GMP inspection of the manufacturing facility by Government of Upper BavariaCentral Medicines Control Bavaria (GMP/GCP).

Initiated CRAMs services in areas of new chemical entity (NCE”) or Generic APIs.

Received original drug substance registration certificate for mycophenolate mofetil from Pharmaceuticals and Medical Devices Agency, Japan.

Third USFDA inspection and classification of the API facility as acceptable.

Received certificate of drug substance registry for Ciclosporin JP from Pharmaceuticals and Medical Devices Agency, Japan.

Fourth USFDA inspection of the Dholka facility and conclusion of inspection as ‘closed’.

Second EU GMP inspection of the manufacturing facility.

Received accreditation certificate of foreign drug manufacturing for non-sterile drugs from Minister of Health, Labthe and Welfare of Japan.

Established a facility at Valthera, Gujarat.

Recognition of the in-house R&D facility located at Valthera by Ministry of Science and Technology, Government of India.

Investment from Helix Investment Holdings Pte. Limited.

First USFDA inspection at the Valthera facility and receipt of establishment inspection report.

Fifth USFDA inspection and received ‘no action indicated’ classification for the facility located at Dholka.

Grant of GMP certification from Food and Drugs Control Administration for Valthera and Dholka units Second USFDA inspection at the facility located in Valthera facility and receipt of establishment inspection report.

Established Joint Venture in Japan pursuant to growing business opportunities in Japan.

Received two ANDA approvals.

Expansion of the company’s business in critical care segment in India.

Commencement of marketing of Mycophenolate Mofetil Capsules USP 250 mg.

Board of the Company permitted the layout plan for the proposed injectable manufacturing unit at Valthera facility.

Received two ANDA approvals.

First shipment of Mycophenolate Sodium Tablets, in US market.

Commenced operations at second API facility at Limbasi.

Third EU GMP inspection of the manufacturing facility located in Dholka.

Completion of the USFDA inspection at the Limbasi facility